3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Glioma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Paraproteinemias
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Interventions
Temozolomide
100
Radiotherapy
49
Magnetic Resonance Spectroscopy
38
Radiation
28
Specimen Handling
25
pembrolizumab
22
Bevacizumab
22
Lomustine
16
Nivolumab
14
Surgical Procedures, Operative
10
atezolizumab
8
Cyclophosphamide
8
Biopsy
8
abemaciclib
7
Ipilimumab
7
fludarabine
6
Radiotherapy, Intensity-Modulated
6
Carboplatin
6
Aminolevulinic Acid
6
olaparib
5
Metformin
5
Drug Therapy
5
Diet, Ketogenic
5
Dianhydrogalactitol
5
poly ICLC
4
cemiplimab
4
Radiosurgery
4
Photons
4
Leukapheresis
4
Immunoglobulin G
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
CLR1404
×
1 year
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled